Fella Chennou1, Alexanne Bonneau-Fortin1, Olivia Portolese1, Lina Belmesk1, Mélissa Jean-Pierre2, Geneviève Côté3, Martha H Dirks2, Prévost Jantchou4,5. 1. CHU Sainte-Justine Research Center, Montreal, QC, Canada. 2. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, CHU Sainte-Justine University Hospital, 3175, ch. côte Sainte-Catherine, Montreal, QC, Canada. 3. Division of Anesthesiology, Department of Pediatrics, CHU Sainte-Justine University Hospital, Montreal, QC, Canada. 4. CHU Sainte-Justine Research Center, Montreal, QC, Canada. prevost.jantchou@umontreal.ca. 5. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, CHU Sainte-Justine University Hospital, 3175, ch. côte Sainte-Catherine, Montreal, QC, Canada. prevost.jantchou@umontreal.ca.
Abstract
BACKGROUND: Digestive endoscopies must be performed within a safe and comfortable environment. We have previously shown that the quality of intravenous sedation is influenced by preoperative stress. AIM: Our primary objective was to compare the effects of oral lorazepam and placebo on the salivary cortisol response of children undergoing a digestive endoscopy. Secondary objectives were the assessment of procedural pain and comfort as well as the occurrence of adverse events. METHODS: Participants were randomized and received either lorazepam, placebo, or no premedication. Saliva was collected upon arrival at the hospital and 1 h following randomization. The sedation protocol included midazolam and fentanyl ± ketamine. Procedural pain was evaluated with the Nurse Assessed Patient Comfort Score (NAPCOMS). Patients completed a postoperative questionnaire. The primary outcome was defined as the proportion of children having a cortisol decrease ≥ 15 nmol/L. RESULTS:101 participants (54 females) were included. The rate of children having a cortisol decrease ≥ 15 nmol/L was 27.3%, 35.3%, and 19.4% for lorazepam, placebo, and no premedication, respectively (p = 0.356). The median (IQR) NAPCOMS pain score was 3.0 (0-6) for lorazepam, 4.4 (0-6) for placebo, and 3.4 (3-4) for no premedication (p = 0.428). With lorazepam, 75.9% of children reported experiencing a comfortable procedure, compared with 41.9% taking placebo and 34.5% with no premedication (p = 0.013). Transient tachycardia was the most frequent intraoperative adverse event, particularly with lorazepam (62.5%, p = 0.029). CONCLUSIONS:Oral lorazepam had no effect on patients' preoperative stress, as measured by salivary cortisol, but was associated with a higher rate of comfortable procedures. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, Identifier NCT03180632.
RCT Entities:
BACKGROUND: Digestive endoscopies must be performed within a safe and comfortable environment. We have previously shown that the quality of intravenous sedation is influenced by preoperative stress. AIM: Our primary objective was to compare the effects of oral lorazepam and placebo on the salivary cortisol response of children undergoing a digestive endoscopy. Secondary objectives were the assessment of procedural pain and comfort as well as the occurrence of adverse events. METHODS:Participants were randomized and received either lorazepam, placebo, or no premedication. Saliva was collected upon arrival at the hospital and 1 h following randomization. The sedation protocol included midazolam and fentanyl ± ketamine. Procedural pain was evaluated with the Nurse Assessed Patient Comfort Score (NAPCOMS). Patients completed a postoperative questionnaire. The primary outcome was defined as the proportion of children having a cortisol decrease ≥ 15 nmol/L. RESULTS: 101 participants (54 females) were included. The rate of children having a cortisol decrease ≥ 15 nmol/L was 27.3%, 35.3%, and 19.4% for lorazepam, placebo, and no premedication, respectively (p = 0.356). The median (IQR) NAPCOMS pain score was 3.0 (0-6) for lorazepam, 4.4 (0-6) for placebo, and 3.4 (3-4) for no premedication (p = 0.428). With lorazepam, 75.9% of children reported experiencing a comfortable procedure, compared with 41.9% taking placebo and 34.5% with no premedication (p = 0.013). Transient tachycardia was the most frequent intraoperative adverse event, particularly with lorazepam (62.5%, p = 0.029). CONCLUSIONS: Oral lorazepam had no effect on patients' preoperative stress, as measured by salivary cortisol, but was associated with a higher rate of comfortable procedures. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov, Identifier NCT03180632.
Authors: Petar Mamula; Jonathan E Markowitz; Kristin Neiswender; Ann Zimmerman; Stephanie Wood; Michael Garofolo; Megan Nieberle; Andria Trautwein; Susan Lombardi; Lynn Sargent-Harkins; Greta Lachewitz; Lisa Farace; Verita Morgan; Anita Puma; Scott D Cook-Sather; Chris A Liacouras Journal: Gastrointest Endosc Date: 2007-02 Impact factor: 9.427
Authors: Alaa Rostom; Erin D Ross; Catherine Dubé; Matthew D Rutter; Thomas Lee; Roland Valori; Ronald J Bridges; Darlene Pontifex; Veronica Webbink; Colin Rees; Carly Brown; Deborah H Whetter; Susan G Kelsey; Robert J Hilsden Journal: Gastrointest Endosc Date: 2013-02 Impact factor: 9.427
Authors: Brian J Ulmer; Jonathan J Hansen; Christine A Overley; Michelle R Symms; Vidyasree Chadalawada; Suthat Liangpunsakul; Eloise Strahl; April M Mendel; Douglas K Rex Journal: Clin Gastroenterol Hepatol Date: 2003-11 Impact factor: 11.382
Authors: Jihui Zhang; Siu-Ping Lam; Alice P S Kong; Ronald C W Ma; Shirley Xin Li; Joey W Y Chan; Mandy W M Yu; Junying Zhou; Michael H M Chan; Chung-Shun Ho; Albert M Li; Xiangdong Tang; Yun-Kwok Wing Journal: Sci Rep Date: 2016-03-01 Impact factor: 4.379